Newsroom
Legal Action Alert for TransMedics Investors
By KlickAnalytics Data Insights | April 11, 2025 10:00AM ET
Key Points
- Multiple law firms are reminding investors of the pending class action lawsuit against TransMedics Group, Inc. with a lead plaintiff deadline of April 15, 2025.
- The lawsuit alleges securities fraud by the company and certain senior executives.
- Investors who suffered losses on their TMDX investment are encouraged to seek potential recovery under federal securities laws.
- The lead plaintiff deadline for joining the class action lawsuit is rapidly approaching.
- Investors have until April 15, 2025, to ask the Court to be appointed to lead the case.
Several law firms, including Levi & Korsinsky, Kessler Topaz Meltzer & Check, BFA Law, Bronstein, Gewirtz & Grossman, and Bleichmar Fonti & Auld LLP, are reminding investors of the pending class action lawsuit against TransMedics Group, Inc. The lead plaintiff deadline for this lawsuit is April 15, 2025. The lawsuit alleges securities fraud by the company and certain of its senior executives, with the class period ranging from February 3, 2022, to February 3, 2025.
Investors who suffered losses on their TransMedics Group, Inc. (NASDAQ: TMDX) investment are being encouraged to explore the possibility of recovering their losses under the federal securities laws. They are advised to contact Joseph E. Levi, Esq., or visit specified websites for more information on how to participate in the class action lawsuit.
The legal action against TransMedics Group, Inc. raises questions about potential securities law violations by the company and its executives. Investors who believe they may have been affected by the alleged securities fraud have until April 15, 2025, to take action. It is important for investors to be aware of their rights and options regarding this class action lawsuit.
As the deadline for the lead plaintiff in the class action lawsuit against TransMedics Group, Inc. approaches, investors are urged to act promptly. The lawsuit seeks to recover damages for investors who purchased or otherwise acquired TransMedics securities during the specified class period. It is crucial for investors to seek out more information and consider their legal options before the deadline passes.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with